RxDoctor Payments DataLook up a doctor →

Farhan Siddiqui, MD

Pulmonary Disease · Spartanburg, SCNPI 1447461579

Payments from drug & device makers

$8,642,552in general payments, 2019–2025

Across 2,922 payments — averaging $2957.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Modernatx, Inc.$3.1M
  • Seqirus USA Inc$1.2M
  • Pfizer$1.1M
  • Vertex$794K
  • Eli Lilly$564K
  • AstraZeneca$444K
  • plus $1.5M from 54 others
$227,913in research payments, 2019–2025

Across 7 payments — averaging $32,559 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Nielsen Biosciences, Inc.$170K
  • Eli Lilly$58K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Modernatx, Inc.937$3,111,600
Seqirus USA Inc943$1,156,847
Pfizer60$1,095,670
Vertex4$794,311
Eli Lilly14$564,064
AstraZeneca109$443,869
Verona Pharma, Inc.28$348,980
GSK167$267,735
Astrazeneca UK Limited3$234,946
Currax Pharmaceuticals LLC24$212,151
Chiesi USA, Inc.18$180,225
Amphastar Pharmaceuticals, Inc.3$133,725
Sanofi42$32,724
Amgen26$20,544
Genentech, Inc.5$18,243
Merck18$10,318
Intuitive Surgical9$4,587
Boehringer Ingelheim59$2,239
Inspire Medical Systems, Inc.14$1,291
United Therapeutics Corporation35$795
Regeneron Healthcare Solutions, Inc.32$735
Electromed, Inc.51$717
Actelion Pharmaceuticals US, Inc.31$710
Takeda Pharmaceuticals U.S.A., Inc.29$651
Philips North America LLC29$532
Gilead22$461
Insmed, Inc.24$387
Mylan Specialty L.p.23$361
Johnson & Johnson(2 entities)19$332
Mallinckrodt Hospital Products Inc.12$278
Sunovion Pharmaceuticals Inc.18$235
Grifols USA, LLC13$213
Novartis13$211
Memed US, Inc.1$178
Nuwellis, Inc.3$172
Bayer8$164
Jazz Pharmaceuticals Inc.6$149
Avadel CNS Pharmaceuticals, LLC6$121
ANI Pharmaceuticals, Inc.7$111
Teva Pharmaceuticals USA, Inc.7$91
Baxter Healthcare3$79
Resmed Corp5$77
Axsome Therapeutics, Inc.4$75
Harmony Biosciences LLC4$74
Advanced Respiratory, Inc4$61
Inogen, Inc.3$56
Genentech USA, Inc.3$47
Edwards Lifesciences1$37
Melinta Therapeutics, LLC2$35
Ambu Inc.1$34
Pulmonx Corporation2$33
Hikma Pharmaceuticals USA2$30
Circassia Inc.2$29
Body Vision Medical Inc.1$23
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$22
Itamar Medical Inc1$18
Arbor Pharmaceuticals, Inc.1$17
Lilly USA, LLC1$17
Vifor Pharma, Inc.1$17
Shire North American Group Inc1$16

How this compares

$8,642,552 in reported general payments places this provider in the 95th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina →

Medicare billing

Part B allowed, 2024
$195,091
Medicare patients
839
Services billed
2,797

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in Spartanburg

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →